A follow-up study on 6-[18F]fluoro-L-dopa uptake in early Parkinson's disease shows nonlinear progression in the putamen.
Identifieur interne : 002587 ( Ncbi/Merge ); précédent : 002586; suivant : 002588A follow-up study on 6-[18F]fluoro-L-dopa uptake in early Parkinson's disease shows nonlinear progression in the putamen.
Auteurs : Anna Brück [Finlande] ; Sargo Aalto ; Elina Rauhala ; Jörgen Bergman ; Reijo Marttila ; Juha O. RinneSource :
- Movement disorders : official journal of the Movement Disorder Society [ 1531-8257 ] ; 2009.
English descriptors
- KwdEn :
- Aged, Brain Mapping, Disease Progression, Female, Fluorodeoxyglucose F18 (diagnostic use), Functional Laterality, Humans, Levodopa (metabolism), Longitudinal Studies, Male, Middle Aged, Nonlinear Dynamics, Parkinson Disease (metabolism), Parkinson Disease (pathology), Parkinson Disease (radionuclide imaging), Positron-Emission Tomography (methods), Postmortem Changes, Putamen (radionuclide imaging), Time Factors.
- MESH :
- chemical , diagnostic use : Fluorodeoxyglucose F18.
- chemical , metabolism : Levodopa.
- metabolism : Parkinson Disease.
- methods : Positron-Emission Tomography.
- pathology : Parkinson Disease.
- radionuclide imaging : Parkinson Disease, Putamen.
- Aged, Brain Mapping, Disease Progression, Female, Functional Laterality, Humans, Longitudinal Studies, Male, Middle Aged, Nonlinear Dynamics, Postmortem Changes, Time Factors.
Abstract
Sixteen subjects with de novo Parkinson's disease (PD) underwent three 6-[18F]fluoro-L-dopa (Fdopa) positron emission tomography (PET) scans during a follow-up time of 5 years (mean +/- SD 5.5 +/- 0.4 years) to study the progression of striatal dopaminergic hypofunction. Throughout the study, the smallest Fdopa uptake values were found in the dorso-caudal part of the putamen contralateral to the side with dominant motor symptoms. The rate of decline in Fdopa uptake in the contralateral putamen was faster in the beginning of the disease and slowed down as the disease progressed. The annual decline in Fdopa influx constant (Ki, unit x 10(-3) min(-1)) was on average 0.5 during the first 2 years and 0.2 during the subsequent 3 years (P = 0.002) in the contralateral putamen. In caudate, the rate of decline in Fdopa values was slower than in the putamen and did not change significantly during the follow-up time, annual decline in the contralateral caudate being 0.1 between baseline and 2 years and 0.3 between 2 and 5 years (P = 0.4). These results suggest that progression of putaminal dopaminergic hypofuncion in PD follows a nonlinear pattern at least in the contralateral side being faster in the beginning of the disease.
DOI: 10.1002/mds.22484
PubMed: 19260097
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 001D90
- to stream PubMed, to step Curation: 001D90
- to stream PubMed, to step Checkpoint: 001F84
Links to Exploration step
pubmed:19260097Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">A follow-up study on 6-[18F]fluoro-L-dopa uptake in early Parkinson's disease shows nonlinear progression in the putamen.</title><author><name sortKey="Bruck, Anna" sort="Bruck, Anna" uniqKey="Bruck A" first="Anna" last="Brück">Anna Brück</name><affiliation wicri:level="4"><nlm:affiliation>Turku PET Centre, University of Turku, Turku, Finland. anna.bruck@utu.fi</nlm:affiliation><country xml:lang="fr">Finlande</country><wicri:regionArea>Turku PET Centre, University of Turku, Turku</wicri:regionArea><placeName><settlement type="city">Turku</settlement><region type="région" nuts="2">Finlande occidentale</region></placeName><orgName type="university">Université de Turku</orgName></affiliation></author><author><name sortKey="Aalto, Sargo" sort="Aalto, Sargo" uniqKey="Aalto S" first="Sargo" last="Aalto">Sargo Aalto</name></author><author><name sortKey="Rauhala, Elina" sort="Rauhala, Elina" uniqKey="Rauhala E" first="Elina" last="Rauhala">Elina Rauhala</name></author><author><name sortKey="Bergman, Jorgen" sort="Bergman, Jorgen" uniqKey="Bergman J" first="Jörgen" last="Bergman">Jörgen Bergman</name></author><author><name sortKey="Marttila, Reijo" sort="Marttila, Reijo" uniqKey="Marttila R" first="Reijo" last="Marttila">Reijo Marttila</name></author><author><name sortKey="Rinne, Juha O" sort="Rinne, Juha O" uniqKey="Rinne J" first="Juha O" last="Rinne">Juha O. Rinne</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2009">2009</date><idno type="doi">10.1002/mds.22484</idno><idno type="RBID">pubmed:19260097</idno><idno type="pmid">19260097</idno><idno type="wicri:Area/PubMed/Corpus">001D90</idno><idno type="wicri:Area/PubMed/Curation">001D90</idno><idno type="wicri:Area/PubMed/Checkpoint">001F84</idno><idno type="wicri:Area/Ncbi/Merge">002587</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">A follow-up study on 6-[18F]fluoro-L-dopa uptake in early Parkinson's disease shows nonlinear progression in the putamen.</title><author><name sortKey="Bruck, Anna" sort="Bruck, Anna" uniqKey="Bruck A" first="Anna" last="Brück">Anna Brück</name><affiliation wicri:level="4"><nlm:affiliation>Turku PET Centre, University of Turku, Turku, Finland. anna.bruck@utu.fi</nlm:affiliation><country xml:lang="fr">Finlande</country><wicri:regionArea>Turku PET Centre, University of Turku, Turku</wicri:regionArea><placeName><settlement type="city">Turku</settlement><region type="région" nuts="2">Finlande occidentale</region></placeName><orgName type="university">Université de Turku</orgName></affiliation></author><author><name sortKey="Aalto, Sargo" sort="Aalto, Sargo" uniqKey="Aalto S" first="Sargo" last="Aalto">Sargo Aalto</name></author><author><name sortKey="Rauhala, Elina" sort="Rauhala, Elina" uniqKey="Rauhala E" first="Elina" last="Rauhala">Elina Rauhala</name></author><author><name sortKey="Bergman, Jorgen" sort="Bergman, Jorgen" uniqKey="Bergman J" first="Jörgen" last="Bergman">Jörgen Bergman</name></author><author><name sortKey="Marttila, Reijo" sort="Marttila, Reijo" uniqKey="Marttila R" first="Reijo" last="Marttila">Reijo Marttila</name></author><author><name sortKey="Rinne, Juha O" sort="Rinne, Juha O" uniqKey="Rinne J" first="Juha O" last="Rinne">Juha O. Rinne</name></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="eISSN">1531-8257</idno><imprint><date when="2009" type="published">2009</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Brain Mapping</term><term>Disease Progression</term><term>Female</term><term>Fluorodeoxyglucose F18 (diagnostic use)</term><term>Functional Laterality</term><term>Humans</term><term>Levodopa (metabolism)</term><term>Longitudinal Studies</term><term>Male</term><term>Middle Aged</term><term>Nonlinear Dynamics</term><term>Parkinson Disease (metabolism)</term><term>Parkinson Disease (pathology)</term><term>Parkinson Disease (radionuclide imaging)</term><term>Positron-Emission Tomography (methods)</term><term>Postmortem Changes</term><term>Putamen (radionuclide imaging)</term><term>Time Factors</term></keywords><keywords scheme="MESH" type="chemical" qualifier="diagnostic use" xml:lang="en"><term>Fluorodeoxyglucose F18</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Levodopa</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Positron-Emission Tomography</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="radionuclide imaging" xml:lang="en"><term>Parkinson Disease</term><term>Putamen</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Brain Mapping</term><term>Disease Progression</term><term>Female</term><term>Functional Laterality</term><term>Humans</term><term>Longitudinal Studies</term><term>Male</term><term>Middle Aged</term><term>Nonlinear Dynamics</term><term>Postmortem Changes</term><term>Time Factors</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Sixteen subjects with de novo Parkinson's disease (PD) underwent three 6-[18F]fluoro-L-dopa (Fdopa) positron emission tomography (PET) scans during a follow-up time of 5 years (mean +/- SD 5.5 +/- 0.4 years) to study the progression of striatal dopaminergic hypofunction. Throughout the study, the smallest Fdopa uptake values were found in the dorso-caudal part of the putamen contralateral to the side with dominant motor symptoms. The rate of decline in Fdopa uptake in the contralateral putamen was faster in the beginning of the disease and slowed down as the disease progressed. The annual decline in Fdopa influx constant (Ki, unit x 10(-3) min(-1)) was on average 0.5 during the first 2 years and 0.2 during the subsequent 3 years (P = 0.002) in the contralateral putamen. In caudate, the rate of decline in Fdopa values was slower than in the putamen and did not change significantly during the follow-up time, annual decline in the contralateral caudate being 0.1 between baseline and 2 years and 0.3 between 2 and 5 years (P = 0.4). These results suggest that progression of putaminal dopaminergic hypofuncion in PD follows a nonlinear pattern at least in the contralateral side being faster in the beginning of the disease.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">19260097</PMID><DateCreated><Year>2009</Year><Month>06</Month><Day>03</Day></DateCreated><DateCompleted><Year>2009</Year><Month>08</Month><Day>19</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1531-8257</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>7</Issue><PubDate><Year>2009</Year><Month>May</Month><Day>15</Day></PubDate></JournalIssue><Title>Movement disorders : official journal of the Movement Disorder Society</Title><ISOAbbreviation>Mov. Disord.</ISOAbbreviation></Journal><ArticleTitle>A follow-up study on 6-[18F]fluoro-L-dopa uptake in early Parkinson's disease shows nonlinear progression in the putamen.</ArticleTitle><Pagination><MedlinePgn>1009-15</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/mds.22484</ELocationID><Abstract><AbstractText>Sixteen subjects with de novo Parkinson's disease (PD) underwent three 6-[18F]fluoro-L-dopa (Fdopa) positron emission tomography (PET) scans during a follow-up time of 5 years (mean +/- SD 5.5 +/- 0.4 years) to study the progression of striatal dopaminergic hypofunction. Throughout the study, the smallest Fdopa uptake values were found in the dorso-caudal part of the putamen contralateral to the side with dominant motor symptoms. The rate of decline in Fdopa uptake in the contralateral putamen was faster in the beginning of the disease and slowed down as the disease progressed. The annual decline in Fdopa influx constant (Ki, unit x 10(-3) min(-1)) was on average 0.5 during the first 2 years and 0.2 during the subsequent 3 years (P = 0.002) in the contralateral putamen. In caudate, the rate of decline in Fdopa values was slower than in the putamen and did not change significantly during the follow-up time, annual decline in the contralateral caudate being 0.1 between baseline and 2 years and 0.3 between 2 and 5 years (P = 0.4). These results suggest that progression of putaminal dopaminergic hypofuncion in PD follows a nonlinear pattern at least in the contralateral side being faster in the beginning of the disease.</AbstractText><CopyrightInformation>(c) 2009 Movement Disorder Society.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Brück</LastName><ForeName>Anna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Turku PET Centre, University of Turku, Turku, Finland. anna.bruck@utu.fi</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aalto</LastName><ForeName>Sargo</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Rauhala</LastName><ForeName>Elina</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Bergman</LastName><ForeName>Jörgen</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Marttila</LastName><ForeName>Reijo</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Rinne</LastName><ForeName>Juha O</ForeName><Initials>JO</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Mov Disord</MedlineTA><NlmUniqueID>8610688</NlmUniqueID><ISSNLinking>0885-3185</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0Z5B2CJX4D</RegistryNumber><NameOfSubstance UI="D019788">Fluorodeoxyglucose F18</NameOfSubstance></Chemical><Chemical><RegistryNumber>46627O600J</RegistryNumber><NameOfSubstance UI="D007980">Levodopa</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D001931">Brain Mapping</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D018450">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D019788">Fluorodeoxyglucose F18</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000176">diagnostic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D007839">Functional Laterality</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D007980">Levodopa</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008137">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D017711">Nonlinear Dynamics</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D010300">Parkinson Disease</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName><QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName><QualifierName MajorTopicYN="N" UI="Q000531">radionuclide imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D049268">Positron-Emission Tomography</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000379">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D011180">Postmortem Changes</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D011699">Putamen</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000531">radionuclide imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D013997">Time Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>3</Month><Day>5</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>3</Month><Day>5</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>8</Month><Day>20</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="doi">10.1002/mds.22484</ArticleId><ArticleId IdType="pubmed">19260097</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Finlande</li></country><region><li>Finlande occidentale</li></region><settlement><li>Turku</li></settlement><orgName><li>Université de Turku</li></orgName></list><tree><noCountry><name sortKey="Aalto, Sargo" sort="Aalto, Sargo" uniqKey="Aalto S" first="Sargo" last="Aalto">Sargo Aalto</name><name sortKey="Bergman, Jorgen" sort="Bergman, Jorgen" uniqKey="Bergman J" first="Jörgen" last="Bergman">Jörgen Bergman</name><name sortKey="Marttila, Reijo" sort="Marttila, Reijo" uniqKey="Marttila R" first="Reijo" last="Marttila">Reijo Marttila</name><name sortKey="Rauhala, Elina" sort="Rauhala, Elina" uniqKey="Rauhala E" first="Elina" last="Rauhala">Elina Rauhala</name><name sortKey="Rinne, Juha O" sort="Rinne, Juha O" uniqKey="Rinne J" first="Juha O" last="Rinne">Juha O. Rinne</name></noCountry><country name="Finlande"><region name="Finlande occidentale"><name sortKey="Bruck, Anna" sort="Bruck, Anna" uniqKey="Bruck A" first="Anna" last="Brück">Anna Brück</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002587 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 002587 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Ncbi
|étape= Merge
|type= RBID
|clé= pubmed:19260097
|texte= A follow-up study on 6-[18F]fluoro-L-dopa uptake in early Parkinson's disease shows nonlinear progression in the putamen.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:19260097" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \
| NlmPubMed2Wicri -a MovDisordV3
| This area was generated with Dilib version V0.6.23. |  |